

Supplementary Table 1. Baseline characteristics of patients in AKI and non-AKI group

Characteristic	Total (n = 512)	Non-AKI (n = 440)	AKI (n = 72)	p-value
Demographic data				
Age (yr)	68.3 ± 15.1	67.8 ± 15.2	71.0 ± 13.8	0.10
Male sex	294 (57.4)	252 (57.3)	42 (58.3)	0.87
Body mass index (kg/m ²)	25.9 ± 15.8	26.2 ± 16.9	24.2 ± 5.7	0.33
Systolic BP (mmHg)	126.3 ± 17.5	126.2 ± 17.4	126.7 ± 17.9	0.83
Diastolic BP (mmHg)	74.1 ± 10.7	74.5 ± 10.7	71.8 ± 10.2	0.047
Comorbidities				
Diabetes mellitus	269 (52.5)	233 (53.0)	36 (50.0)	0.64
Dyslipidemia	201 (39.3)	170 (38.6)	31 (43.1)	0.48
Coronary artery disease	242 (47.3)	205 (46.6)	37 (51.4)	0.45
Chronic kidney disease	140 (27.3)	105 (23.9)	35 (48.6)	<0.001
Laboratory parameters				
Hemoglobin (g/dL)	12.1 ± 2.3	12.3 ± 2.2	11.3 ± 2.2	<0.001
White blood cells (×10 ³ /μL)	7.4 ± 3.0	7.3 ± 2.9	7.6 ± 3.6	0.40
Platelet (×10 ³ /μL)	213.3 ± 96.7	214.9 ± 97.7	203.6 ± 90.6	0.36
Calcium (mg/L)	8.7 ± 0.6	8.7 ± 0.6	8.5 ± 0.6	0.003
Phosphorous (mg/L)	3.7 ± 0.8	3.7 ± 0.7	3.8 ± 0.9	0.40
Albumin (g/dL)	3.8 ± 0.9	3.8 ± 1.0	3.6 ± 0.5	0.02
Uric acid (mg/L)	6.0 ± 2.3	5.9 ± 2.2	6.5 ± 2.8	0.046
Glucose (mg/L)	129.6 ± 54.6	127.8 ± 51.4	140.6 ± 70.3	0.07
eGFR (mL/min/1.73 m ²)	76.5 ± 28.7	78.0 ± 26.0	66.8 ± 40.6	0.002
Total cholesterol (mg/dL)	151.3 ± 44.7	151.9 ± 44.6	147.4 ± 45.4	0.44
LDL-C (mg/dL)	87.5 ± 36.4	88.2 ± 35.9	84.1 ± 39.3	0.49
HDL-C (mg/dL)	42.6 ± 13.9	42.9 ± 14.0	41.2 ± 13.7	0.42
Na (mmol/L)	138.8 ± 3.6	138.9 ± 3.6	138.3 ± 3.6	0.19
K (mmol/L)	4.1 ± 0.5	4.1 ± 0.5	4.1 ± 0.7	0.99
tCO ₂ (mmol/L)	24.4 ± 3.8	24.4 ± 3.8	24.4 ± 3.9	0.98
HbA1c (%)	7.0 ± 1.6	7.0 ± 1.6	6.8 ± 1.5	0.46
C-reactive protein (mg/L)	22.7 ± 40.2	22.2 ± 40.5	25.4 ± 39.2	0.56
NT-proBNP (pg/mL)	6,137.1 ± 8,639.9	5,484.0 ± 7,718.5	9,674.6 ± 11,983.6	<0.001
Dipstick				0.05
Neg	213 (45.8)	191 (48.5)	22 (31.0)	
Trace	70 (15.1)	59 (15.0)	11 (15.5)	
1+	90 (19.4)	73 (18.5)	17 (23.9)	
2+	57 (12.3)	43 (10.9)	14 (19.7)	
≥3+	35 (7.5)	28 (7.1)	7 (9.9)	
uACR	983.6 ± 1,774.4	851.2 ± 1,649.0	1,436.9 ± 2,123.4	0.14
Medications				
Anti-hypertensive agents				
Beta-blockers	387 (75.6)	336 (76.4)	51 (70.8)	0.31
Calcium channel blockers	245 (47.9)	212 (48.2)	33 (45.8)	0.71
Furosemide	406 (79.3)	342 (77.7)	64 (88.9)	0.03
Spironolactone	212 (41.4)	178 (40.5)	34 (47.2)	0.28
Anti-diabetic agents				
SGLT2 inhibitor	111 (21.7)	96 (21.8)	15 (20.8)	0.85
Insulin	123 (24.0)	104 (23.6)	19 (26.4)	0.61
Others	164 (32.0)	137 (31.1)	27 (37.5)	0.28

Data are expressed as mean ± standard deviation or number (%).

AKI, acute kidney injury; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; K, potassium; LDL-C, low-density lipoprotein cholesterol; Na, sodium; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SGLT2, sodium-glucose cotransporter-2; tCO₂, total carbon dioxide; uACR, urinary albumin to creatinine ratio.